___

• 1. Omata M, Kanda T, Wei L, Yu M-L, Chuang W-L, Ibrahim A, et al. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatology international. 2016;10(5):681-701. 2. Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018 Aug;69(2):461-511. 3. Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012 Jul;55 Suppl 1:S43-8. 4. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clinical Microbiology and Infection. 2015;21(11):1020-6. 5. Grad R, Thombs BD, Tonelli M et al. Recommendations on hepatitis C screening for adults. CMAJ. 2017 Apr 24; 189(16): E594–604. 6. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014 Feb;60(2):392-420. 7. Architect system Anti HCV, Abbott Laboratories; [cited 2019 Feb 18]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf5/P050042c.pdf 8. Kuhnert WL. Department of Health and Human Services; [cited 2019 Feb 18]. Available from: https://www.cdc.gov/hepatitis/hcv/pdfs/architectletter_5-24-07.pdf 9. Centers for Diseases and Prevention. Signal-to-Cut–Off Ratios for Commercially Available Assays; [cited 2019 Feb 18]. Available from: https://www.cdc.gov/hepatitis/hcv/labtesting.htm 10. Altuğlu İ, Gürsel D, Aksoy A, Orman M, Erensoy S. Anti-HCV sinyal/eşik değer oranının Hepatit C virüs enfeksiyonu tanısında rolü ve önemi. Ege Tıp Dergisi 2011;50(4): 223-8.